Santen Launches Ryjunea® in Germany for the Treatment of Pediatric Myopia
Following European Commission approval on June 2, 2025, Santen Pharmaceutical Co., Ltd. (hereinafter Santen) today announced that Ryjunea® (development code: STN1012701), is now available in Germany. Germany is the first market to launch Ryjunea®, with other launches across Europe to follow.
Valuation expectations are rising. If SYD-101 succeeds in both the EU and U.S., Sydnexis could command a biotech valuation in the range of $1.5 billion to $2 billion, based on typical pre-commercial revenue multiples. Investor interest is expected to accelerate in Q4 as FDA decision timelines approach.